Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD340 FITC

Anti-Hu CD340 FITC

Regulatory status

RUO

Antigen

CD340

Clone

24D2

Format

FITC

Reactivity

Human

Application

FC (QC tested)

Excitation laser

blue (488 nm)

Variant

100 tests

1F-832-T100

Ask for delivery term HERE

198.00 USD

Variant

100 tests

1F-832-T100

Ask for delivery term HERE

198.00 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG1

Specificity

The mouse monoclonal antibody 24D2 recognizes an extracellular epitope of human CD340 (HER-2), a type I transmembrane protein expressed by mesenchymal stem cells, B-lymphoblastic leukemia cells, subsets of C-ALL blasts, and and various types of carcinomas.

Workshop

HCDM listed

Application

FC (QC tested)

Application details

Flow cytometry: The reagent is designed for analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 10⁶ cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.

Reactivity

Human

Immunogen

NIH-3T3/huCD340 cells

Preparation

Purified antibody is conjugated with fluorescein isothiocyanate (FITC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Formulation

Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

ERBB2, NEU, NGL, HER2, TKR1, MLN 19

Antigen description

The oncoprotein ErbB2/HER2 (human epidermal growth factor receptor 2), also known as Neu or CD340, is a 185 kDa transmembrane tyrosine kinase of cell surface growth factor receptor family. It is present in a wide variety cell types of normal human fetal and adult tissues and is frequently overexpressed in human carcinomas (e.g. in 20-30% cases of breast cancer cells). Activation of ErbB2 triggers intracellular signalling events, which are essential for cell growth and differentiation. In the last 20 years ErbB2 antigen has become very important marker and therapy target in patient care.

Entrez Gene ID 2064

UniProt ID P04626

Separation of MCF-7 cells stained using anti-human CD340 (24D2) FITC antibody (concentration in sample 0.5 μg/ml, red-filled) from MCF-7 cells stained using mouse IgG1 isotype control (MOPC-21) FITC antibody (concentration in sample 0.5 μg/ml, same as CD340 FITC concentration, black-dashed) in flow cytometry analysis (surface staining).

General references:

Arora P, Cuevas BD, Russo A, Johnson GL, Trejo J: Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion. Oncogene. 2008 Mar 31
PubMed

Northey JJ, Chmielecki J, Ngan E, Russo C, Annis MG, Muller WJ, Siegel PM: Northey JJ, Chmielecki J, Ngan E, Russo C, Annis MG, Muller WJ, Siegel PM: Signaling through ShcA is required for TGF-{beta} and Neu/ErbB-2 induced breast cancer cell motility and invasion. Mol Cell Biol. 2008 Mar 10
PubMed

Yuan W, Wang W, Cui B, Su T, Ge Y, Jiang L, Zhou W, Ning G: Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry. Endocr Relat Cancer. 2008 Mar;15(1):343-50.
PubMed

Hicks DG, Kulkarni S: HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol. 2008 Feb;129(2):263-73.
PubMed

Dowsett M, Hanna WM, Kockx M, Penault-Llorca F, Rüschoff J, Gutjahr T, Habben K, van de Vijver MJ: Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod Pathol. 2007 May;20(5):584-91.
PubMed

Koeppen HK, Wright BD, Burt AD, Quirke P, McNicol AM, Dybdal NO, Sliwkowski MX, Hillan KJ: Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology. 2001 Feb;38(2):96-104.
PubMed

Product specific references:

Bühring HJ, Sures I, Jallal B, Weiss FU, Busch FW, Ludwig WD, Handgretinger R, Waller HD, Ullrich A: The receptor tyrosine kinase p185HER2 is expressed on a subset of B-lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia. Blood. 1995 Sep 1;86(5):1916-23.
PubMed

Bühring HJ, Battula VL, Treml S, Schewe B, Kanz L, Vogel W: Novel markers for the prospective isolation of human MSC. Ann N Y Acad Sci. 2007 Jun;1106:262-71.
PubMed

Tran T, Diniz MO, Dransart E, Gey A, Merillon N, Lone YC, Godefroy S, Sibley C, Ferreira LC, Medioni J, Oudard S, Johannes L, Tartour E: A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice. Clin Cancer Res. 2016 Aug 15;22(16):4133-44.
PubMed

Bailey TA, Luan H, Tom E, Bielecki TA, Mohapatra B, Ahmad G, George M, Kelly DL, Natarajan A, Raja SM, Band V, Band H: A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells. J Biol Chem. 2014 Oct 31;289(44):30443-58.
PubMed